BrainsWay to Report Third Quarter 2021 Financial Results on November 17, 2021

Rhea-AI Summary

BrainsWay Ltd. (NASDAQ: BWAY), a leader in noninvasive neurostimulation for mental health, will report its Q3 2021 financial results on November 17, 2021, before U.S. market opening. The company plans to host a conference call at 8:30 AM ET to discuss the results and update on operations. BrainsWay is recognized for its Deep TMS™ technology, which is FDA-cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The call will be available for replay for 30 days.

BURLINGTON, Mass. and JERUSALEM, Nov. 03, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2021 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, November 17, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, November 17, 2021
Time:	8:30 AM Eastern Time
United States:	877-407-3982
International:	201-493-6780
Conference ID:	13723993
Webcast:	http://public.viavid.com/index.php?id=146897

The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Contacts: 
BrainsWay:
Scott Areglado
SVP and Chief Financial Officer
617-771-2287
SAreglado@brainsway.com

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com 

FAQ

When will BrainsWay report its Q3 2021 financial results?

BrainsWay will report its Q3 2021 financial results on November 17, 2021.

What time is the BrainsWay conference call for Q3 2021 results?

The conference call will take place at 8:30 AM Eastern Time.

What is the purpose of the BrainsWay conference call on November 17, 2021?

The conference call will discuss Q3 2021 financial results and provide an update on business operations.

How can I access the BrainsWay conference call?

You can access the conference call by dialing the U.S. number 877-407-3982 or the international number 201-493-6780.

Is there a webcast available for the BrainsWay conference call?

Yes, a webcast will be available at the provided link and will also be available for replay for 30 days.